Evaluation of the efficacy and safety of Bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the selective estrogens, menopause and response to therapy (SMART) trials

Journal of Women's Health

Volumn 23, Issue 1, 2014, Pages 18-28

  Pinkerton, Joann V ^a   Abraham, Lucy ^b   Bushmakin, Andrew G ^c   Cappelleri, Joseph C ^c   Racketa, Jill ^c   Shi, Harry ^c   Chines, Arkadi A ^c   Mirkin, Sebastian ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; PLACEBO; RALOXIFENE; BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTROGEN; INDOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AMENORRHEA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMOTION; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MIDDLE AGED; MOOD; MORBIDITY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SLEEP QUALITY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASOMOTOR DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; HEALTH STATUS; HOT FLASHES; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TIME;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HEALTH STATUS; HOT FLASHES; HUMANS; INDOLES; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891689570     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2013.4392     Document Type: Article

References (30)

1. Komm BS. A new approach to menopausal therapy: The tissue selective estrogen complex. Reprod Sci 2008;15:984-992.
2. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-1038.
3. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/ conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-1024.
4. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): Incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-1044.
5. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/ conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-1052.
6. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: A randomized, controlled trial. Menopause 2009;16: 1116-1124.
7. Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329-335.
8. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/ conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281-289.
9. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/ conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010;13:132-140.
10. North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012;19:257-271.
11. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
12. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44.
13. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292: 1573-1580.
14. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Menopause 2012;19:387-395.
15. Pinkerton JV, Chines AA, Racketa J, Mirkin S. Bazedoxifene/ conjugated estrogens (BZA/CE): Effect on sleep parameters in postmenopausal women. Menopause 2010;17: 1237-1238. Abstract P-53.
16. Pinkerton JV, Chines AA, Racketa J, Mirkin S. Menopauserelated quality of life and satisfaction in postmenopausal women treated with bazedoxifene/ conjugated estrogens (BZA/CE). Menopause 2010;17:1219. Abstract S-12.
17. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: Development and psychometric properties. Maturitas 1996;24:161-175.
18. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, eds. Measuring functioning and well-being: The medical outcomes study approach. Durham, NC: Duke University Press, 1992:235-259.
19. Hill CD, Fehnel SE, Bobula JD, Yu H, McLeod LD. Development and preliminary validation of the Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ). Menopause 2007;14:1047-1055.
20. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003;56:395-407.
21. Col NF, Guthrie JR, Politi M, Dennerstein L. Duration of vasomotor symptoms in middle-Aged women: A longitudinal study. Menopause 2009;16:453-457.
22. Fenton A, Chines A, Mirkin S. Effect of bazedoxifene paired with conjugated estrogens on vasomotor symptoms over 2 years of therapy. Oral presentation at the 4th Triennial Scientific Meeting of the Asia Pacific Menopause Federation; September 26-29, 2010; Sydney, Australia .
23. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83:686-692.
24. Hammar ML, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA. Tibolone and low-dose continuous combined hormone treatment: Vaginal bleeding pattern, efficacy and tolerability. BJOG 2007;114:1522-1529.
25. Wattanakumtornkul S, Chichareon S, Geater A, Suwan K. Compliance with hormone replacement therapy at Songklanagarind Hospital. J Obstet Gynaecol Res 2003;29:380-387.
26. Manonai J, Theppisai U, Suchartwatnachai C, Jetsawangsri T, Chittacharoen A. Compliance with hormone replacement therapy in Thai women. Maturitas 2003;44:201-205.
27. Archer DF, Lobo RA, Pan K, et al. Safety and tolerability of bazedoxifene/conjugated estrogens in postmenopausal women: Findings from a 1-year, randomized, placebo- and active-controlled, phase 3 trial. Menopause 2011;18:1355-1356. Abstract P-25.
28. Pinkerton JV, Pan K, Abraham L, Racketa J, Chines AA, Mirkin S. Effects of bazedoxifene/conjugated estrogens on sleep parameters and health-related quality of life in postmenopausal women. Menopause 2011;18:1346. Abstract S-13.
29. Gallagher JC, Lindsay R, Pan K, Mirkin S, Chines A. Effects of bazedoxifene/conjugated estrogens on bone mineral density and bone turnover markers in postmenopausal women: A double-blind, randomized, placebo- and activecontrolled phase 3 study. J Bone Miner Res 2011;26:S46. Abstract 1133.
30. Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene- conjugated estrogens: A randomized controlled trial. Obstet Gynecol 2013;121:959-968.